Effect of the administration of an oral hyaluronan formulation on clinical and biochemical parameters in young horses with osteochondrosis

J. U. Carmona; D. Argüelles; R. Deulofeu; D. Martínez-Puig; M. Prades

doi:10.3415/VCOT-09-01-0001

Veterinary and Comparative Orthopaedics and Traumatology, Inhaltsverzeichnis

Vet Comp Orthop Traumatol 2009; 22(06): 455-459
DOI: 10.3415/VCOT-09-01-0001

Original Research

Schattauer GmbH

Effect of the administration of an oral hyaluronan formulation on clinical and biochemical parameters in young horses with osteochondrosis

J. U. Carmona

¹Departament de Medicina i Cirurgia Animal, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain

²Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia

,

D. Argüelles

²Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia

,

R. Deulofeu

³Servei de Bioquímica i Genètica Molecular. Hospital Clínic Universitari de Barcelona, Universitat de Barcelona, Barcelona, Spain

,

D. Martínez-Puig

⁴R&D Area, Bioibérica S.A., Barcelona, Spain

,

M. Prades

¹Departament de Medicina i Cirurgia Animal, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain

› Institutsangaben

Abstract

Summary

The aim of this study was to evaluate the clinical and biochemical effects of the administration of oral hyaluronan (Hyal-Joint® [HJ]) on young horses with osteochondrosis (OC). Our hypotheses were that HJ administration is safe, would decrease the degree of synovial effusion and the concentration of nitric oxide (NO) and prostaglandin E2 (PGE2) in synovial fluid, and would increase the concentration of hyaluronic acid (HA) in plasma and synovial fluid. Eleven young horses with tarsocrural OC were included in a randomised, doubleblinded, placebo-controlled pilot clinical trial. Six horses received 250 mg/day HJ for 60 days (T60) and five horses received a placebo. The initial values of the degree of synovial effusion, NO, PGE2 and HA concentrations in synovial fluid and HA concentration in plasma were obtained. The horses were evaluated in terms of the same parameters at the end of treatment (T60) and 30 days thereafter (T90). The differences between the groups for each of the parameters evaluated at T0, T60 and T90 were not significant. Nevertheless, the horses treated with HJ tended to show a lower score for synovial effusion as well as higher HA, NO and PGE2 concentrations in synovial fluid, but these differences were non-significant. At a dose of 250 mg/day, HJ did not produce any adverse clinical effects and was well tolerated by the horses.

Keywords

Equine osteochondrosis - oral hyaluronan - nitric oxide - prostaglandin E2 - synovial fluid

Volltext

Referenzen

References
1 Wittwer C, Hamann H, Rosenberger E. et al Prevalence of osteochondrosis in the limb joints of South German Coldblood horses. J Vet Med A Physiol Pathol Clin Med 2006; 53: 531-539.
2 McIlwraith CW. Clinical aspects of osteochondritis dissecans. In McIlwraith CW. and Trotter GW. (editors) Joint disease in the horse.. Philadelphia: WB Saunders Company; 1996: 369-374.
3 Robert C, Valette JP, Denoix JM. Correlation between routine radiographic findings and early racing career in French trotters. Equine Vet J Suppl 2006; 36: 473-488.
4 van Weeren PR. Etiology, diagnosis, and treatment of OC(D). Clin Tech Equine Pract 2006; 5: 248-258.
5 Jeffcott LB. Osteochondrosis: an international problem for the horse industry. J Equine Vet Scien 1996; 16: 32-37.
6 McIlwraith CW. General pathobiology of the joint and response to injury. In McIlwraith CW, and Trotter GW. (editors) Joint disease in the horse.. Philadelphia: WB Saunders Company; 1996: 40-70.
7 Howard RD, McIlwraith CW. Hyaluronan and its use in the treatment of equine joint disease. In McIlwraith CW, and Trotter GW. (editors) Joint disease in the horse. Philadelphia: WB Saunders Company; 1996: 270-280.
8 Popot MA, Bonnaire J, Guéchot J. et al Hyaluronan in horses: physiological production rate, plasma and synovial fluid concentrations in control conditions and following sodium hyaluronate administration. Equine Vet J 2004; 36: 482-487.
9 Wang CT, Lin YT, Chiang BL. et al High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006; 14: 1237-1247.
10 Frean SP, Abraham LA, Lees P. In vitro stimulation of equine articular cartilage proteoglycans synthesis by hyaluronan and carprofen. Res Vet Sci 1999; 67: 181-188.
11 Tung JT, Venta PJ, Caron JP. Inducible oxide nitric expression in equine articular chondrocytes: effects of antiinflammatory compounds. Osteoarthritis Cartilage 2002; 10: 5-12.
12 Tung JT, Venta PJ, Eberhart SW. et al Effects of anti-arthritis preparations on gene expression and enzyme activity of cyclooxygenase-2 in cultured equine chondrocytes. Am J Vet Res 2002; 63: 1134-1139.
13 Carmona JU, Arguelles D, Climent F. et al Autologous Platelet concentrates as a treatment of horses with osteoarthritis: a preliminary pilot clinical study. J Equine Vet Sci 2007; 27: 167-170.
14 Archer S. Measurement of Nitric Oxide in biological models. FASEB J 1993; 7: 340-360.
15 von Rechenberg B, McIlwraith CW, Akens MK. et al Spontaneous production of nitric oxide (NO), prostaglandin (PGE2), and neutral metalloproteinases (NMPs) in media of explant cultures of equine synovial membrane and articular cartilage from normal and osteoarthritic joints. Equine Vet J 2000; 32: 140-150.
16 Guechot J, Laudat A, Loria A. et al Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558-63.
17 Dawson B, Trapp RG, Trapp R. Basic & Clinical Biostatistics. Fourth edition. USA. McGraw-Hill Medical 2004; 416
18 de Grauw JC, Brama PA, Wiemer P. et al Cartilage-derived biomarkers and lipid mediators of inflammation in horses with osteochondritis dissecans of the distal intermediate ridge of the tibia. Am J Vet Res 2006; 67: 1156-1162.
19 Gangl M, Serteyn D, Lejeune JP. et al A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions. Res Vet Sci 2007; 82: 68-75.
20 van den Boom R, van de Lest CH, Bull S. et al Influence of repeated arthrocentesis and exercise on synovial fluid concentrations of nitric oxide, prostaglandin E2 and glycosaminoglycans in healthy equine joints. Equine Vet J 2005; 37: 250-256.
21 Lappegård KT, Riesenfeld J, Brekke OL. et al Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. Ann Thorac Surg 2005; 79: 917-923.
22 Bergin BJ, Pierce SW, Bramlage LR. et al Oral hyaluronan gel reduces post operative tarsocrural effusion in the yearling Thoroughbred. Equine Vet J 2006; 38: 375-378.
23 Kawcak CE, Frisbie DD, Trotter GW. Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation. Am J Vet Res 1997; 58: 1132-1140.
24 Maneiro E, de Andrés MC, Fernández-Sueiro JL. et al The biological action of hyaluronan on human osteoarthritic articular chondrocytes: the importance of molecular weight. Clinical and Experimental Rheumatology 2004; 22: 307-312.
25 Viitanen M, Bird J, Maisi P. et al Differences in the concentration of various synovial fluid constituents between the distal interphalangeal joint, the meta-carpophalangeal joint and the navicular bursa in normal horses. Res Vet Sci 2000; 69: 63-67.